Lawrence Fong, a genitourinary oncologist and expert in immunotherapy for solid tumors, was named scientific director of the Immunotherapy Integrated Research Center at Fred Hutchinson Cancer Center. He will begin the role July 1, 2024.
The University of Texas MD Anderson Cancer Center and AmMax Bio, Inc. announced a worldwide exclusive license agreement and clinical trial agreement to develop and advance AmMax’s AMB-066 monoclonal antibody therapy as a first-in-class treatment option for patients with colorectal cancer and minimal residual disease as well as those with MRD in other solid tumors.
